Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Nasal spray monograph petition denied

This article was originally published in The Tan Sheet

Executive Summary

FDA rejects a petition submitted by SinoFresh Research Labs to include nasal sprays containing .05% cetylpyridinium chloride in the tentative final monograph for Oral Antiseptic Drug Products. The agency panel did not consider nasal antiseptics when it evaluated OTC oral antiseptics, FDA states. Consequently, the firm's nasal and sinus care product is an unapproved new drug due to insufficient marketing history. The agency also concludes safety and efficacy data provided by the Venice, Fla. firm is inadequate. SinoFresh petitioned to reopen the administrative record for the monograph to allow for additional data in March 2003 1("The Tan Sheet" April 7, 2003, p. 7)...

You may also be interested in...

Cetylpyridinium Nasal Spray Status As Category I Oral Antiseptic Requested

Inclusion of a nasal spray containing .05% cetylpyridinium chloride in FDA's tentative final monograph for Oral Antiseptic Drug Products is requested by SinoFresh Research Labs in a March 24 citizen petition

Ready, Set, Guidance: FDA Releases Final Details Ahead Of ASCA Pilot Launch

A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.

With Preservative-Free Alaway Eye Drops, Bausch Expands OTC Portfolio Of Planned Spin-Off

Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals. 





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts